Application of CIK (cytokine-induced killer) cell and antibody in combined treatment of cancer

The invention provides an application of CIK cell and antibody in combined treatment of cancer, the antibody comprises a PD-1-targeting first antigen binding domain and a CD3-targeting second antigen binding domain, two anti-tumor targets of PD-1 and CD3 can be targeted at the same time, and the targeting and effectiveness of treatment are improved; the bispecific antibody has a brand-new amino acid structure and can be combined with a target antigen in a high affinity manner; the bispecific antibody is combined with CIK cells for use, and immune connection is established between tumor cell nucleus CIK cells through CD3 and PD-1 antigen binding domains, so that the anti-tumor activity can be remarkably improved, and the lifetime of animals can be prolonged; the culture mode of the CIK cells is optimized, and the CIK cells with higher biological activity are obtained. 本发明提供了一种CIK细胞与抗体联合治疗癌症的用途，所述抗体包括靶向PD-1的第一抗原结合域和靶向CD3的第二抗原结合域，可同时靶向PD-1和CD3两种抗肿瘤靶点，提高治疗的靶向性和有效性；所述双特异性抗体具有全新的氨基酸结构，可与目标抗原高亲和力结合；所述双特异性抗体与CIK细胞联用，